Global Access Scorecard

The Global Access Scorecard uses building blocks of existing Environmental, Social, Governance (ESG) principles and applies them to the biotech, healthcare, and drug manufacturing context. It analyzes net benefit to all stakeholders, including the patient/consumer, company employees, and company investors.

The Scorecard includes three key criteria evaluating whether the technology will increase access to medical care and healthcare in underserved global communities: (1) Target outcomes and target equity of the company and its technology (2) Scientific viability of the product (3) Corporate governance and business structure.

Access to affordable medicines is a critical component of health, and the lack of equitable access for many treatments, cures, and other health innovations creates hardship and healthcare barriers. The current system, where a drug is approved before conversations begin about global access, too often means that underserved patients obtain medicines too late, or not at all. These delays can lead to worsening health disparities, sometimes to the point of crisis. RSV is committed to assembling a broad coalition of impact investors that use the Global Access Scorecard in early investment decisions, and believe that widespread adoption of the Global Access Scorecard will improve health outcomes globally.